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Background: Change in breast density may predict outcome of women receiving adjuvant hormone therapy for breast cancer. We
performed a prospective clinical trial to evaluate the impact of inherited variants in genes involved in oestrogen metabolism and
signalling on change in mammographic percent density (MPD) with aromatase inhibitor (AI) therapy.
Methods: Postmenopausal women with breast cancer who were initiating adjuvant AI therapy were enrolled onto a multicentre,
randomised clinical trial of exemestane vs letrozole, designed to identify associations between AI-induced change in MPD
and single-nucleotide polymorphisms in candidate genes. Subjects underwent unilateral craniocaudal mammography before and
following 24 months of treatment.
Results: Of the 503 enrolled subjects, 259 had both paired mammograms at baseline and following 24 months of treatment and
evaluable DNA. We observed a statistically significant decrease in mean MPD from 17.1 to 15.1% (Po0.001), more pronounced in
women with baseline MPDX20%. No AI-specific difference in change in MPD was identified. No significant associations between
change in MPD and inherited genetic variants were observed.
Conclusion: Subjects with higher baseline MPD had a greater average decrease in MPD with AI therapy. There does not appear to
be a substantial effect of inherited variants in biologically selected candidate genes.
There is considerable interpatient variation in the mammographic
appearance of the breast, in part because of differences in the
characteristics of different components of breast tissue (Pinsky and
Helvie, 2010). Fibroglandular tissue absorbs more of the X-ray
beam and therefore appears light, whereas fat absorbs less of the
X-ray beam and is darker. In clinical practice, mammographic
percent density (MPD) has been estimated by radiologists using
visual assessment to categorise percent breast density into quartiles
(American College of Radiology, 2003). Methods have also been
developed to quantitate MPD, including manual, computer-aided,
and fully computerised methodologies (Byng et al, 1994; Boyd et al,
1995; Zhou et al, 2001; Wei et al, 2004; Martin et al, 2006).
High breast density as assessed by mammography is one of the
strongest risk factors for breast cancer (Boyd et al, 2005). Factors
definitely associated with breast density include age, menopausal
status, body mass index (BMI), and exogenous hormone use. In
general, MPD declines with increasing age, during the menopausal
transition, and with increasing body weight (Boyd et al, 1998;
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Vachon et al, 2000; Martin and Boyd, 2008). Exposure to steroidal
sex hormones may also play a role in an individual’s MPD.
Numerous reports have demonstrated increased MPD with
exposure to hormone replacement therapy (Rutter et al, 2001;
Boyd et al, 2006). However, reports from studies evaluating
associations between endogenous circulating hormone concentra-
tions and MPD have yielded mixed results (Aiello et al, 2005;
Greendale et al, 2005; Tamimi et al, 2005; Warren et al, 2006;
Martin and Boyd, 2008).
Treatment with the selective oestrogen receptor modulator
tamoxifen has been shown to decrease MPD, especially in women
aged p45 years (Cuzick et al, 2004). Benefit from tamoxifen has
been shown to be greater in women with a greater reduction in
MPD (Cuzick et al, 2011; Kim et al, 2012). It is unknown whether a
similar association between decrease in MPD and decreased risk of
breast cancer recurrence is present in postmenopausal women
treated with aromatase inhibitor (AI) therapy.
Aromatase is a key enzyme required for the final step in the
conversion of androgens to oestrogens. Aromatase inhibitors,
which inhibit the production of oestrogen, have been shown to
decrease the risk of new primary breast cancer and breast cancer
recurrence in postmenopausal women (Burstein et al, 2010;
Dowsett et al, 2010; Goss et al, 2011). However, the impact of AI
therapy on MPD is uncertain. Two small studies evaluating the
impact of AI therapy on MPD found no change over 24 months
(Cigler et al, 2010, 2011), and another detected a nonstatistically
significant decrease in MPD over 12 months (Prowell et al, 2011).
A case–control study demonstrated a 45% reduction in MPD in
14% of 387 women treated with AI therapy for an average of
10 months, which was not statistically different from matched
controls (Vachon et al, 2013).
Population-based studies have demonstrated that genetic effects
can affect MPD (Boyd et al, 2002; Douglas et al, 2008; Ursin et al,
2009; Greenwood et al, 2011; Varghese et al, 2012). In twins,
heritable factors account for about two-thirds of the variation in
MPD (Boyd et al, 2002). However, few specific inherited variants
have been identified to be associated with MPD (Haiman et al,
2003; Warren et al, 2006; Olson et al, 2007; Li et al, 2010;
Lindstrom et al, 2011; Ellingjord-Dale et al, 2012). Therefore,
although there appears to be a heritable component to MPD, the
contributing genetic variants have not been fully elucidated.
We conducted a prospective randomised trial to test the
effects on MPD of two AIs (letrozole (Femara, Novartis, Basel,
Switzerland) vs exemestane (Aromasin, Pfizer, New York, NY,
USA)) in postmenopausal women with early-stage breast cancer
who were initiating adjuvant AI therapy. Mammographic percent
density was assessed using a validated computer-assisted method
(Martin et al, 2006; Douglas et al, 2008) and included multiple
prospective quality measures to minimise bias. The primary
objectives of the study were to determine the changes in MPD
following 24 months of AI therapy and to determine whether the
change in MPD is correlated with genetic variants in CYP19A1, the
gene that encodes aromatase.
MATERIALS AND METHODS
Eligible patients were recruited from August 2005 through July
2009 to the prospective Exemestane and Letrozole Pharmaco-
genomics (ELPh) trial (clinicaltrials.gov no. NCT00228956).
This trial was conducted by the Consortium on Breast Cancer
Pharmacogenomics (COBRA), which includes the Indiana University
Bren and Melvin Simon Cancer Center (IU), the University of
Michigan Comprehensive Cancer Center (UM), and the Sidney
Kimmel Comprehensive Cancer Center at Johns Hopkins
University (JH). Detailed inclusion and exclusion criteria
have previously been described (Henry et al, 2008). In brief,
postmenopausal women with stage 0–III hormone receptor-
positive breast cancer were eligible. Patients were excluded if they
had bilateral mastectomy or prior radiation to the contralateral
(unaffected) breast. All indicated surgery, chemotherapy, and
radiation therapy for breast cancer were completed before
enrollment. Prior tamoxifen was permitted. The protocol was
approved by the Institutional Review Boards of all participating
study sites (JH, IU and UM), and all enrolled patients provided
written informed consent. The clinical trial was reviewed by
an independent Data and Safety Monitoring Committee on a
bi-annual basis.
Study design. Following enrollment, women were randomly
assigned to treatment with exemestane (25mg) or letrozole
(2.5mg) daily for 2 years. Randomisation was stratified based
on prior tamoxifen (yes/no), prior chemotherapy (yes/no), and
bisphosphonate therapy (yes/no). Patients underwent a single
craniocaudal view mammogram of the contralateral breast at the
baseline and 24 month visits. Whole blood was collected at the
baseline visit for DNA extraction and genotyping. Serum samples
were obtained at baseline and after 3 months of AI therapy
to determine oestrogen concentrations.
Mammographic assessment. Two study sites acquired mammo-
graphic images using General Electric machines (Fairfield, CT,
USA) (JH and UM) and the other site used a Hologic machine
(Bedford, MA, USA) (IU). During the conduct of the study, the
study sites transitioned from film mammography to digital
mammography following the results of the Digital Mammographic
Imaging Screening Trial (Pisano et al, 2005). However, with a few
exceptions, each patient was evaluated with the same technology
(film or digital mammography) at both time points. Film
mammograms were digitised with a laser scanner designed for
mammogram digitisation. If patients had digital mammograms,
raw data were obtained and sent to the radiologist for processing
and analysis whenever possible. Mammograms were excluded from
analysis if only processed digital data were available or if presence
of breast implants prevented accurate assessment of MPD.
Although the mammograms were performed for research
purposes, all mammographic images were reviewed by a radiologist
(MAH and RP) within 45 days of the procedure to confirm that
there were no clinically relevant findings. If such findings were
detected, they were provided to the caregiver for appropriate
evaluation.
In order to avoid interobserver variability, a single Mammo-
graphic Quality Standards Act-approved breast radiologist (MAH)
with more than 25 years of experience in mammography
performed all density assessments within a short period of time
at the conclusion of the clinical trial, blinded to patient number,
time point, and AI medication. This reader, who had prior
experience using the assessment method, underwent training on a
learning set of images immediately before analysing the cases
in this study. As previously reported, the within-individual r for
assessment of percent density using this technique was 0.96, and
the mean absolute difference in intrareader variability was 3.5%
with a root mean squared error of 4.5% (Douglas et al, 2008).
Mammographic percent density was assessed for each mammo-
gram using two different methodologies. The radiologist first
evaluated all the mammograms using the Breast Imaging
Reporting and Data System (BIRADS) density classification, in
which mammograms are grouped using visual estimation of MPD
into four quartiles ranging from category 1 (o25% fibroglandular)
to category 4 (475% fibroglandular). After completion of all of the
BIRADS assessments, the radiologist then interactively used the
computer program Mammographic Density ESTimator (MDEST)
to quantitatively estimate the MPD as the Reference Standard.
The MDEST enhances the image, detects the breast boundary,
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and analyses the grey-level histogram as previously reported
(Zhou et al, 2001). The dense area is then segmented using
adaptive thresholding techniques and its percentage relative to the
breast area is calculated. The radiologist visually compared the
original and segmented mammograms on the display workstation,
and could interactively adjust the threshold for segmentation and/
or breast border chosen by the computer if necessary. True dense area
was determined for each mammogram by multiplying percent density
by the total breast area. The value is given in mm2, based on a pixel
size of 0.8mm by 0.8mm. The Reference Standard is the method that
was prospectively identified in the clinical protocol as the method that
would be used for the analysis of the primary objective.
Sample processing and genotyping. Serum was obtained from
each subject at baseline and after 3 months of AI therapy, when
drug levels would have reached steady state. Samples were analysed
for oestrogen and its metabolites, including oestrone sulphate
(E1S), using gas chromatography tandem mass spectroscopy
(PharmaNet, Richboro, PA, USA). In brief, analytes and deuterated
internal standards were extracted from 0.4ml of human plasma
using BondElut Certify solid-phase cartridges (Agilent Techno-
logies, Santa Clara, CA, USA). The E1S was eluted from the
cartridges with ethyl acetate and then underwent three separate
derivatisations: (1) reaction with pentafluorobenzoyl chloride, (2)
reaction with O-(2,3,4,5,6-pentaflurorobenzyl)-hydroxylamine
hydrochloride, and (3) reaction with MSTFA. The derivatised
E1S was then separated by gas chromatography and detected by
tandem mass spectrometry using negative ion chemical ionisation.
The lower limit of quantification (LOQ) was 3.13 pgml 1, and the
upper LOQ was 800 pgml 1.
Whole blood was collected from each participant at the baseline
study visit. The DNA was extracted from whole blood using
Qiafilter Blood DNA Maxi kit (Qiagen, Inc., Valencia, CA, USA).
At the time of protocol development, candidate single-nucleotide
polymorphisms (SNPs) in 24 genes were identified through a priori
review of the literature based on their potential functional
significance in a variety of AI-associated effects, including change
in breast density, change in bone density, and development
of treatment-emergent symptoms including arthralgias and hot
flashes. Before conducting the analysis of associations between
genetic variants and change in breast density reported in this
paper, the decision was made by the Investigators to limit the
analysis to the 13 genes that we identified as playing a biologic role
in the development or maintenance of breast density. Therefore,
only SNPs in genes involved in oestrogen metabolism (COMT,
CYP19A1), oestrogen receptor (ER) signalling (ESR1, ESR2, PGR),
AI drug metabolism (CYP2A6, CYP3A5), and coregulation
of ER (EP300, NCOA1, NCOA2, NCOA3, NCOR1, NCOR2) were
included; SNPs in EZH2, NRIP, PELP1, and neurotransmitter and
neuropeptide signalling (HTR1A, HTR2A, SCL6A4, HCRT,
HCRTR1, HCRTR2) were excluded. In total, 135 candidate variants
in 13 individual genes were identified and genotyped. One variant
(rs9340941) that did not meet Hardy–Weinberg equilibrium, one
(rs1256066) for which genotype could not be determined in480%
of subjects, and 6 (rs9322348, rs9340872, rs9341069, rs9341074,
rs9341081, rs9341084) with a minor allele frequency (MAF) of 0
were excluded from the analysis. A total of 127 variants in 13 genes
were included in the final analysis. The rs numbers, MAF, and
genotype frequencies for each analysed SNP are listed in
Supplementary Tables S1 and S2.
Genotyping for all SNPs, except for the CYP3A5 and CYP2A6
SNPs, was performed using the BioTroveOpenArray platform
(Applied Biosystems, Inc., Foster City, CA, USA). The CYP3A5 *3
was genotyped using the Taqman assay (Life Technologies,
Carlsbad, CA, USA) (C__26201809_30). Genotyping for CYP2A6
was performed as previously described (Desta et al, 2011).
Genotype quality control was performed before analysis of the
genetic associations. For quality control purposes, B10% of the
samples were randomly selected and genotyped in duplicate using
the same assay, and the overall concordance rate was 97%.
Statistical analysis. The primary end point of the ELPh trial was
the correlation between absolute change in MPD with 2 years of
AI therapy (either exemestane or letrozole) and inherited genetic
variants in the aromatase gene, encoded by CYP19. Our initial
power and sample size calculation was based on a 20% dropout
rate among 500 recruited patients. We estimated the power to be
81% in order to detect an absolute 1.0% change in MPD with
2 years of AI therapy, with a 7% s.d. The power to detect a similar
size of CYP19 dominance effect on both drugs’ effect on MPD is
42%, given a MAF of 0.20. The type I error in both tests was controlled
at 5% each. After the study was concluded, we had data from only 259
patients to test the drug effect and genetic effect hypotheses, which
reduced the power to 63% and 20%, respectively.
Initially, mean MPD and true dense area was determined for all
subjects at baseline, as well as for subjects with available paired
baseline and 24-month mammograms. Percentage change in MPD
was defined as (24-month MPD minus baseline MPD) divided by
baseline MPD. Percentage change in true dense area was defined as
(24-month true dense area minus baseline true dense area) divided
by baseline true dense area. Mean percentage change for either
MPD or true dense area was calculated by averaging the individual
percentage change values for each subject. The t-tests were used to
compare MPD and true dense area between baseline and
24 months in all subjects. Univariate and multivariate analyses
were performed to study effects of covariates on baseline MPD or
true dense area and change in MPD or true dense area. The E1S
values that were below the lower LOQ were changed to the lower
LOQ (3.13 pgml 1), and those values that were above the upper
LOQ were changed to the upper LOQ (800 pgml 1).
Hardy–Weinberg disequilibrium tests were conducted for each
SNP, with a P-value threshold of 0.001 to account for the multiple
testing. The associations between the candidate SNPs and either
baseline or absolute change in MPD with 2 years of AI therapy
were analysed either without or with justifying for BMI and/or
prior chemotherapy. Three genetic models, specifically dominant,
recessive, and additive, were used to test for the associations
between SNPs and MPD or true dense area. For analyses
performed using the recessive model, SNPs with p5 subjects
homozygous for the variant allele were excluded. For patients with
2-year follow-up data, absolute change in breast density was
used as the dependent variable. We used PLINK software (http://
pngu.mgh.harvard.edu/purcell/plink) to perform genotyping data
analysis. Default parameters were used for PLINK software. In
order to account for multiple genetic comparisons with 127 SNPs,
statistical significance was defined as a P-value ofo0.00039 based
on Bonferroni correction.
RESULTS
Patient characteristics. A total of 503 subjects enrolled on the
ELPh trial (Figure 1). From the baseline analyses, 94 subjects were
excluded for the following reasons: (1) technical error (n¼ 1),
(2) breast implants prevented accurate assessment of breast
density (n¼ 6), (3) no mammography at baseline (n¼ 4), and
(4) no raw data available (either film mammograms were digitised
or only processed digital mammogram data were available; n¼ 83).
Therefore, a total of 409 subjects had evaluable baseline mammo-
grams with raw digital data available for assessment. Genotype data
were available for 385 of the 409 subjects (94.1%) with baseline
mammograms. The other 24 subjects did not have DNA available for
a variety of reasons, including technical errors, inability to obtain
blood at baseline, or insufficient quantity of DNA.
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Of the 503 subjects enrolled on the ELPh trial, 299 (59.4%)
completed at least 18 months of AI therapy on study and were
potentially evaluable for the primary end point. The remaining 204
(40.6%) subjects discontinued study participation before 18
months, principally because of toxicities of the AI to which they
were assigned, as previously described (Henry et al, 2012). Of the
299 subjects, 26 were excluded for the following reasons: (1) no
mammography at 24 months (n¼ 15), (2) breast implants that
confounded interpretation of breast density (n¼ 6), (3) technical
error (n¼ 1), and (4) film mammogram at baseline and digital
mammogram at 24 months (n¼ 4). Therefore, 273 subjects who
remained on the assigned treatment had evaluable mammograms
at both baseline and 24 months, and genotype data were available
for 259 (94.9%) of these subjects (51.5% of initially enrolled
subjects).
Clinical characteristics of the evaluable subjects with both
genotype data and either baseline only or with paired mammo-
grams are listed in Table 1. Approximately one-third of subjects
received prior tamoxifen, and about half of patients had received
hormone replacement therapy (HRT) in the past.
Baseline mammographic density. Of the 385 subjects with
evaluable baseline mammograms, the mean MPD assessed by
the Reference Standard method was 17.8% (s.d. 11.1%; Table 1).
Of the 259 subjects with both mammograms available for analysis,
the mean baseline MPD was 17.1% (s.d. 10.7%). Of the 259
subjects, 82 (31.7%) had baseline MPD X20%.
There was a statistically significant correlation between baseline
MPD and age (P¼ 0.038) and BMI (Po0.0001). Patients who had
received prior chemotherapy had a higher baseline MPD (20.2%
(s.d. 11.6%)) compared with those who had not (16.1% (s.d.
10.3%), Po0.0003). No statistically significant associations were
detected with baseline E1S, prior tamoxifen, prior HRT, duration
of prior tamoxifen or HRT, or time since discontinuation of
tamoxifen or HRT (Table 2 and data not shown). Multivariate
analysis revealed that BMI and prior chemotherapy remained
statistically significantly associated with baseline MPD (Table 2).
There was also a statistically significant association between
prior chemotherapy and baseline true dense area on both
univariate and multivariate analyses. Patients who had received
prior chemotherapy had a higher true dense area (3005mm2 (s.d.
2019)) compared with those who had not (2547mm2 (s.d. 1571),
P¼ 0.013). No other statistically significant associations were
identified with any of the other factors listed in Table 2.
Change in breast density with AI therapy. Of the 259 subjects
with both baseline and 24-month mammograms and genotype
data available, there was a statistically significant absolute mean
decrease in MPD of 1.9% (s.d. 4.9%), which corresponds to an
average percentage decrease of 5.6% (s.d. 34.7%; Table 3).
Two-thirds of subjects (171 of 259) had a decrease in MPD with
AI therapy (Figure 2). The baseline MPD of those subjects whose
MPD decreased with AI therapy was 19.4% (s.d. 10.9%), whereas
the baseline MPD of those subjects whose MPD was stable or
increased was 12.6% (s.d. 8.8%). For those subjects with baseline
MPDX20%, the average absolute decrease in MPD with 2 years of
4 unavailable BL mammogram
6 BL mammograms with implants
1 incorrect breast imaged
83 without digital raw data available
503 enrolled subjects
14 unavailable DNA24 unavailable DNA
299 completed >18 months
AI therapy
15 unavailable 24 month mammogram
6 mammograms with implants
1 incorrect breast imaged
4 with film/raw pair
409 baseline images
analysed
273 BL-24 month pairs
analysed
385 evaluable
baseline images
259 evaluable
BL-24 month pairs
Figure 1. Patient flow diagram.
Table 1. Baseline characteristics of patients who underwent
mammographic assessment at baseline only or at both baseline and after
24 months of AI therapy
Patients with both
mammograms
(n¼259)
Patients with only
BL mammogram
(n¼385)
Median age, years (range) 60 (35–84) 59 (35–84)
Race
White 231 (89%) 339 (88%)
Black 22 (8.5%) 36 (9.4%)
Other 6 (2.3%) 10 (2.6%)
Weight, kg (s.d.) 80.3 (17.4) 79.3 (17.4)
Body mass index (s.d.) 30.2 (6.3) 29.9 (6.3)
Prior tamoxifen 83 (32%) 124 (32%)
Prior hormone
replacement therapy
13 744 (53%) 187 (49%)
Prior chemotherapy 111 (43%) 167 (43%)
Assigned aromatase inhibitor
Letrozole 139 (54%) 188 (49%)
Exemestane 120 (46%) 197 (51%)
Baseline BIRADS density score
BIRADS 1 29 (11.2%) 42 (10.9%)
BIRADS 2 131 (51%) 190 (49%)
BIRADS 3 96 (37%) 147 (38%)
BIRADS 4 3 (1.2%) 6 (1.6%)
Baseline reference
standard MPD, % (s.d.)
17.1% (10.7) 17.8% (11.1)
Baseline true dense area,
mm2 (s.d.)
2701 (1873) 2746 (1792)
Abbreviations: AI¼ aromatase inhibitor; BIRADS¼Breast Imaging Reporting and Data
System; BL¼baseline; MPD¼mammographic percent density.
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AI therapy was 4.7% (s.d. 5.5%), whereas for those subjects with
baseline MPD o20%, the average absolute decrease in MPD was
0.6% (s.d. 4.0%). This difference was statistically significant
(Po0.00001).
Analysis of the baseline and 24-month mammograms in this
clinical trial using BIRADS density classification, the standard
method used clinically, demonstrated similar findings to those
presented above using the computer-assessed Reference Standard
method. As assessed using BIRADS density classification, 203
subjects (78.4%) had stable BIRADS, 47 (18.1%) experienced a
decrease, and 9 (3.5%) experienced an increase (Supplementary
Table S3). Using logistic regression, the decrease in BIRADS
category with 24 months of AI therapy was statistically
significantly associated with a greater baseline BIRADS category
(b  0.22, Po0.0001).
In univariate analysis, there was a statistically significant
association between absolute decrease in MPD and both higher
baseline MPD (Po0.0001) and lower baseline BMI (Po0.002;
Table 4). No association was detected between absolute change in
MPD and age, baseline E1S, change in E1S, prior chemotherapy,
prior tamoxifen, prior HRT, duration of prior tamoxifen or HRT,
or time since discontinuation of tamoxifen or HRT (Table 4 and
data not shown). The absolute change in MPD did not differ
according to which AI the subjects received (exemestane  1.7%,
letrozole  2.1%, P¼ 0.95). On multivariate analysis, only baseline
MPD remained statistically significant (Table 4).
Analysis of associations between absolute change in true dense
area and the same factors listed above only identified a statistically
significant association with baseline MPD, which was present on
both univariate and multivariate analyses. In contrast to the
association with change in MPD, there was no association
identified between change in true dense area and baseline BMI
(P¼ 0.17; Table 4).
Associations between candidate genetic variants and breast
density. After adjustment for multiple comparisons, no statisti-
cally significant associations were identified between inherited
genetic variants in candidate genes and pretreatment (baseline)
MPD or true dense area. Similarly, after correction for multiple
comparisons, no SNPs in any candidate genes were significantly
associated with absolute change in MPD because of treatment with
either of the AIs for 2 years (n¼ 259).
DISCUSSION
In this prospective clinical trial, we demonstrated that treatment
with 2 years of adjuvant AI therapy results in a statistically
significant decrease in MPD. Importantly, we found that subjects
with higher baseline MPD experienced a greater absolute reduction
in MPD during therapy than those with lower baseline MPD using
both the Reference Standard method and the standard BIRADS
density classification method used in the clinic. In addition, in the
total population, there were no detectable significant associations
between absolute change in MPD and any of the candidate
inherited genetic variants.
Table 2. Associations between clinical characteristics and baseline
mammographic percentage density
Univariate Multivariate
Characteristic b P-value b P-value
Mammographic percentage density
Age 0.11 0.038 NA
Baseline body mass index 0.47 o0.0001  0.46 o0.0001
Baseline oestrone sulphate 0.09 0.092 NA
Prior tamoxifen 0.05 0.34 NA
Prior chemotherapy 0.18 o0.0003 0.14 0.001
Prior hormone replacement
therapy
0.04 0.42 NA
True dense area
Age 0.05 0.32 NA
Baseline body mass index 0.09 0.07  0.08 0.11
Baseline oestrone sulphate 0.02 0.08 NA
Prior tamoxifen 0.03 0.58 NA
Prior chemotherapy 0.13 0.013 0.12 0.02
Prior hormone replacement
therapy
0.018 0.73 NA
Abbreviation: NA¼ not assessed.
Table 3. Change in mammographic percent density (MPD) and true dense area with 24 months of AI therapy
All patients Exemestane Letrozole
Time point Mean MPD s.d. P-valuea Mean MPD s.d. P-valuea Mean MPD s.d. P-valuea P-valueb
MPD (%) N¼259 N¼ 120 N¼139
Baseline 17.1 10.7 16.1 9.4 18.0 11.6 0.15
24 Months 15.1 9.5 o0.001 14.3 8.3 o0.001 15.9 10.3 o0.001 0.19
Mean absolute change 1.9 4.9  1.7 4.2  2.1 5.5 0.95
Mean percentage changec 5.6% 34.7%  5.8% 30.8% 5.5% 37.9 0.55
True dense area (mm2)
N¼259 N¼ 120 N¼139
Baseline 2701 1873 2577 1436 2809 2180 0.32
24 Months 2521 1812 o0.001 2405 1249 0.006 2621 2185 0.005 0.34
Mean absolute change  180 722 172 671  187 765 0.85
Mean percentage changec 2.0% 31.9%  1.6% 29.9% 2.3% 33.6% 0.86
Abbreviations: AI¼ aromatase inhibitor; N¼ number. Values at each time point, as well as absolute and relative change over 24 months are given.
aThe P-values denote change from baseline within treatment group, paired t-test.
bComparison between exemestane and letrozole, Student’s t-test.
cAverage of each subject’s individual percentage change.
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Our findings are similar to those previously reported by Prowell
et al (2011) and Vachon et al (2013), both of whom reported small
decreases in MPD with approximately a year of AI therapy. In two
small substudies derived from the MAP.1 and MAP.2 prevention
trials of AI therapy, no significant decrease in MPD was observed
with 1 to 2 years of therapy (Cigler et al, 2010, 2011). Although we
demonstrated a statistically significant absolute decrease in both
MPD and true breast density during treatment, the magnitude
of the decrease is comparable to what has been reported in
postmenopausal women who are not receiving anti-oestrogen
therapy (Freedman et al, 2001). Importantly, the average age of
subjects in Freedman’s study was 52 years, which is 8 years
younger than our cohort. Research has shown greater declines in
breast density between the ages of 45 and 55 years, with less change
in breast density at older ages (Maskarinec et al, 2006). Prior
research has also demonstrated relatively stable MPD over time in
postmenopausal women with a BMI 430 kgm 2 (Maskarinec
et al, 2006). Therefore, the decrease in MPD over 2 years observed
in this study may in fact be clinically relevant given the
characteristics of the enrolled patient cohort.
The observation that those with higher baseline MPD had a
greater decrease in MPD during AI therapy confirms a similar
finding recently reported by Vachon et al (2013). In addition, this
observation is clinically important, as others have demonstrated
that (1) high MPD is associated with breast cancer risk (Boyd et al,
2005) and (2) a decrease in MPD is associated with a decreased risk
of developing breast cancer and better breast cancer outcomes
(Kerlikowske et al, 2007; Cuzick et al, 2011; Kim et al, 2012;
Li et al, 2013). A population-based study of women without breast
cancer revealed a decreased risk of breast cancer in women whose
BIRADS density category was 2 or 3 at study entry, and which
decreased over an average of 3 years (Kerlikowske et al, 2007). In a
tamoxifen prevention study, Cuzick et al (2011) reported no
statistically significant reduction in risk of breast cancer for those
whose MPD decreased by o10%. Similarly, postmenopausal
women with breast cancer who experienced a relative reduction
in MPD of 420% during adjuvant tamoxifen therapy had a 50%
decrease in the risk of breast cancer mortality (Li et al, 2013).
Finally, in a retrospective study of women with nonmetastatic
breast cancer, Kim et al (2012) reported a trend towards an
association between a lesser decrease in MPD with AI therapy and
increased risk of disease recurrence (hazard ratio 7.11 (95% CI
0.90–56.37), P¼ 0.06). However, the patients in the study of
Kim et al (2012) were younger and only 16% were treated with AI
monotherapy. Therefore, the applicability of these findings to a
postmenopausal population of breast cancer survivors treated with
upfront AI therapy remains uncertain.
Importantly, only two-thirds of patients in our study experi-
enced a decrease in MPD with AI therapy. It remains unclear why
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Figure 2. Waterfall plot demonstrating absolute change in mammographic percent density (MPD) with aromatase inhibitor (AI) therapy for all
subjects who underwent both baseline and month 24 mammogram assessment (n¼259).
Table 4. Univariate and multivariate analyses of associations between
clinical characteristics and absolute change in mammographic
percentage density (MPD)
Univariate Multivariate
Characteristic b P-value b P-value
Mammographic percentage density
Age 0.065 0.30 NA
Baseline body mass index 0.19 0.002 0.036 0.57
Baseline oestrone sulphate (E1S) 0.036 0.56 NA
% Change in E1S between
baseline and 3 months
0.054 0.39 NA
Prior tamoxifen 0.085 0.18 NA
Prior chemotherapy 0.11 0.08 0.042 0.46
Prior hormone replacement
therapy
0.081 0.20 NA
Baseline mammographic
percentage density
0.46 o0.0001 0.47 o0.0001
AI medication (exemestane vs
letrozole)
0.037 0.55 NA
True dense area
Age 0.03 0.64 NA
Baseline body mass index 0.086 0.17 0.060 0.32
Baseline oestrone sulphate (E1S) 0.028 0.65 NA
% Change in E1S between
baseline and 3 months
0.094 0.13 NA
Prior tamoxifen 0.10 0.11 NA
Prior chemotherapy 0.10 0.11 0.07 0.27
Prior hormone replacement
therapy
0.05 0.43 NA
Baseline mammographic
percentage density
0.28 o0.0001 0.26 o0.0001
AI medication (exemestane vs
letrozole)
0.011 0.86 NA
Abbreviations: AI¼ aromatase inhibitor; NA¼not assessed.
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the other one-third of patients had an increase in MPD with
therapy (Figure 2). One possible explanation for the lack of a
decrease is the low MPD in these subjects at baseline (mean
12.6%), which may limit further decreases in MPD. However, the
15 (5.8%) subjects who experienced an absolute increase in MPD
of 45% did not all have low MPD before treatment initiation, as
the median baseline value was 12.9%, and ranged from 4.7 to
35.3%. This finding is concerning clinically given the findings of
worse breast cancer outcomes or no breast cancer risk reduction in
patients who experienced less reduction in MPD with endocrine
therapy, as described above (Cuzick et al, 2011; Kim et al, 2012;
Li et al, 2013). Similarly, increasing breast density over 3 years
in women without a history of breast cancer has been
associated with an increased risk of breast cancer (Kerlikowske
et al, 2007). Therefore, the possibility that an increase in MPD
with AI therapy portends a poor prognosis is deserving of
further study.
In multivariate analysis, we demonstrated correlations between
lower baseline MPD and both higher BMI and prior treatment
with chemotherapy, which are consistent with previously reported
findings (Vachon et al, 2000; Kim et al, 2012). We also
demonstrated correlations between greater decrease in MPD and
higher baseline MPD, which was also consistent with previously
reported findings by Kim et al (2012) but inconsistent with the
MAP prevention trials (Cigler et al, 2010, 2011). We failed to detect
any associations between baseline MPD and either age or prior
tamoxifen use in our postmenopausal cohort.
The strengths of this study include that it was a relatively large
prospective trial, and that subjects were randomly assigned to
treatment with one of two different AIs from different classes
(steroidal vs nonsteroidal). In addition, the method used to
determine MPD has previously been validated (Martin et al, 2006),
including use in a study evaluating genetic associations with breast
density (Douglas et al, 2008), and had multiple prospective quality
measures in place to minimise intraobserver variability and other
sources of bias as described in the Materials and Methods section.
Importantly, we analysed the raw data files rather than processed
digital images for all digital mammograms. As data processing
methods can differ between manufacturer and over time, care was
taken not to introduce variability into the mammogram findings.
This issue must be considered when evaluating results of studies
that analysed mammogram data using clinical databases, which
typically store only processed images.
A potential limitation of this study, as has been noted in other
studies of AI therapy, is the large treatment discontinuation rate
due primarily to treatment-emergent toxicity (Henry et al, 2012). It
is unknown whether the development of side effects could be
associated with unidentified factors that also affect change in breast
density. However, our results are similar to those from Prowell et al
(2011), in which no subjects discontinued therapy, suggesting that
the high rate of treatment discontinuation may not have had a
great impact. Another limitation is the unavoidable lack of an
untreated group, as it is uncertain how much of a decrease in MPD
related to ageing would have been seen in the absence of AI
therapy.
Review of the literature reveals a large number of previously
reported clinical studies that have also failed to observe consistent
associations between SNPs and breast density in either healthy
women or patients with breast cancer (Haiman et al, 2002, 2003;
Hong et al, 2003, 2004; Warren et al, 2006; Olson et al, 2007;
Li et al, 2010; Lindstrom et al, 2011). Few studies have evaluated
associations between change in MPD with endocrine therapy and
inherited variants. Consistent with the previously reported studies,
we did not identify any statistically significant associations between
inherited genetic variants and baseline MPD. In addition, we were
unable to identify any associations between inherited variants and
change in MPD with AI therapy, although, as described above, the
statistical power for this analysis was limited because of the high
rate of treatment discontinuation.
In summary, we report a decrease in mammographic breast
density with 2 years of AI therapy in the majority of treated
patients, with a greater decrease in those with higher MPD at
baseline. This finding has potential clinical implications, as other
studies have reported associations between greater reductions in
MPD during endocrine therapy and better breast cancer outcomes
(Cuzick et al, 2011; Kim et al, 2012). It remains unknown whether
change in MPD with AI therapy may be a useful early marker for
monitoring effectiveness of adjuvant treatment.
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